新型免疫原性细胞死亡基因分型在胶质母细胞瘤中的预后价值

Prognostic value of novel immune prototype cell death genotyping in glioblastoma

目的探究免疫原性细胞死亡(ICD)基因在胶质母细胞瘤(GBM)中的潜在机制和预后价值。方法下载癌症基因组图谱(TCGA)数据库中的GBM样本信息,并获取ICD基因,同时进行基因分型,再进行整合生物信息学验证基因分型的预后价值,最后进行预后模型的构建。结果通过共识聚类获得了2种与ICD基因相关的亚型,ICD高亚型(风险)组与不良的预后、PTEN基因高突变、高基质评分、高免疫评分有关。重要的是,本研究还构建了基于ICD特征的GBM新分类系统。结论本研究首次使用免疫原性细胞死亡基因进行基因分型,并成功构建预后模型。

Objective To investigate the potential mechanism and prognostic value of immunogenic cell death(ICD)genes in glioblastoma(GBM).Methods Information on GBM samples from The Cancer Genome Atlas(TCGA)database was downloaded,and ICD genes were obtained,along with genotyping,followed by integrated bioinformatics to verify the prognostic value of genotyping,and finally prognostic model construction.Results Two subtypes associated with the ICD gene were obtained by consensus clustering,and the high ICD subtype(risk)group was associated with poor prognosis,high mutations in the PTEN gene,high stromal score,and high immune score.Importantly,this study also constructed a new classification system for GBM based on ICD characteristics.Conclusion This study is the first to use immunogenic cell death genes for genotyping and to successfully construct a prognostic model.